Review paper on circulating tumor DNA in colorectal cancer
Review paper on circulating tumor DNA in colorectal cancer
Dr. Thomas Winder, Prof. Armin Gerger, Prof. David Tougeron
GI CONNECT members authored a paper in Tumor Biology which looks to the future for circulating tumor DNA in colorectal cancer. View the paper and download slides of the key highlights.Dr. Thomas Winder
Medical Oncologist
University Teaching Hospital Feldkirch
Austria
Dr. Thomas Winder is board certified for haematology and medical oncology. Since January 2020 he has been Head of the Department for Haematology and Oncology at the University Teaching Hospital Feldkirch, Austria. In addition, since 2017 he has been President of the Swiss Tumor Molecular Institute in Zürich Switzerland. Dr. Winder’s research focuses on molecular markers to individualize medical treatment of cancer patients. He achieved his expertise in internationally renowned laboratories at University of Southern California, Norris Comprehensive Cancer Center, Los Angeles and University Hospital Zürich, Switzerland. His research activity has been honoured by several national and international awards and high impact publications.
Dr. Thomas Winder has no relevant financial relationships to disclose.
Prof. Armin Gerger
Medical Oncologist
Medical University of Vienna
Austria
Prof. Armin Gerger has no relevant financial relationships to disclose.
Prof. David Tougeron
GI Medical Oncologist
Poitiers University Hospital
France
Dr. David Tougeron is a professor of gastroenterology at Poitiers University Hospital, France. His clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer. Dr. Tougeron has participated in more than 40 clinical trials in digestive oncology and has co-authored more than 50 articles, editorials and book chapters. After a Ph.D. in immune response in colorectal cancer, Dr. Tougeron completed a postdoctoral position at the Mayo Clinic, U.S., in colorectal cancer chemosensitivity. His research is currently focussing on colorectal cancer, particularly colorectal cancer with microsatellite instability and predictive biomarkers of response to targeted therapies. He presently holds professional positions in different organisations, notably the Fédération Francophone de Cancérologie Digestive (FFCD).
Prof. David Tougeron has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Amgen, AstraZeneca, Bayer, BMS, Merck Serono, MSD, Pierre Fabre, Roche, Sanofi and Servier.
|
0 min
|
2017
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.